{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:13:30Z","timestamp":1771038810061,"version":"3.50.1"},"reference-count":33,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"unspecified","delay-in-days":298,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. Psychiatr."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933821022434_sec1\"><jats:title>Background<\/jats:title><jats:p>Paliperidone 3-monthly (PP3M) long-acting injection has proven efficacy and effectiveness in schizophrenia. Little is known of its effectiveness in other diagnoses.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933821022434_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>All patients starting PP3M were followed up for 2\u00a0years. Main outcome measures were relapse and discontinuation from PP3M.<jats:italic>Post hoc<\/jats:italic>we examined outcomes in those switched back to one monthly paliperidone (PP1M) long-acting injection.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933821022434_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Overall, 186 patients were followed-up. At the 2-year end point, 110 patients (59%) were still receiving PP3M, and 129 (70%) were receiving some form of paliperidone long-acting injection. Discontinuation from paliperidone long-acting injections (PPLAIs) was more likely with a nonschizophrenia diagnosis (hazard ratio [HR] for continuation 0.429 [95% confidence intervals (CI) \u2013 0.21, 0.87<jats:italic>p<\/jats:italic>\u00a0=\u00a00.018)), and prior clozapine use [in PP3M patients; HR for discontinuation 1.87 [95% CI \u2013 1.05, 3.30<jats:italic>p<\/jats:italic>\u00a0=\u00a00.032]). Relapse occurred in 20 (11%) of those receiving PP3M. Relapse on PP3M and PPLAIs was more likely in nonschizophrenia diagnosis (HR 0.17 for remaining relapse-free [95% CI \u2013 0.06, 0.50;<jats:italic>p<\/jats:italic>\u00a0=\u00a00.001]; HR 0.21 [95% CI \u2013 0.08, 0.58<jats:italic>p<\/jats:italic>\u00a0=\u00a00.002], respectively), polypharmacy in PP3M patients (HR for relapse 7.91 [95% CI \u2013 3.73, 22.9;<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001]) and PPLAI patients (HR for relapse 6.45 [95% CI \u2013 2.49, 16.5;<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001]), and prior clozapine use in PP3M patients (HR for relapse 6.11 [95% CI \u2013 1.82, 20.5;<jats:italic>p<\/jats:italic>\u00a0=\u00a00.003]) and PPLAI patients (HR for relapse 4.52 (95% CI \u2013 1.51, 13.5;<jats:italic>p<\/jats:italic>\u00a0=\u00a00.007).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933821022434_sec4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Outcomes with PP3M are excellent in practice, even when used outside its formal license. PP3M was relatively more effective in those with an F20 schizophrenia diagnosis and in those never before considered for or prescribed clozapine.<\/jats:p><\/jats:sec>","DOI":"10.1192\/j.eurpsy.2021.2243","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:01:16Z","timestamp":1635246076000},"source":"Crossref","is-referenced-by-count":8,"title":["Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: A 2-year naturalistic follow-up study"],"prefix":"10.1192","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-4122","authenticated-orcid":false,"given":"Ivana","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-6302","authenticated-orcid":false,"given":"Phoebe","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-1065","authenticated-orcid":false,"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1710","authenticated-orcid":false,"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"S0924933821022434_r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.01.047"},{"key":"S0924933821022434_r25","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw038"},{"key":"S0924933821022434_r33","doi-asserted-by":"publisher","DOI":"10.1177\/2045125317749740"},{"key":"S0924933821022434_r30","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705006309"},{"key":"S0924933821022434_r1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09416"},{"key":"S0924933821022434_r22","first-page":"156","article-title":"Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"BiolPsychiatry"},{"key":"S0924933821022434_r5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.529672"},{"key":"S0924933821022434_r32","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102611"},{"key":"S0924933821022434_r12","unstructured":"12. Janssen-Cilag Ltd. Summary of product characteristics. INVEGA 3\u00a0mg, 6\u00a0mg, 9\u00a0mg prolonged-release tablets; 2017. https:\/\/www.medicines.org.uk\/emc\/."},{"key":"S0924933821022434_r10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2010.00815.x"},{"key":"S0924933821022434_r4","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0068"},{"key":"S0924933821022434_r9","first-page":"263","article-title":"Remission and employment status in schizophrenia and other psychoses: one-year prospective study in Croatian patients treated with risperidone long acting injection","volume":"28","author":"Mihaljevic-Peles","year":"2016","journal-title":"Psychiatr Danub"},{"key":"S0924933821022434_r3","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000155"},{"key":"S0924933821022434_r14","unstructured":"14. Accord Healthcare Limited. Risperidone 0.5\/1\/2\/3\/4\/6\u00a0mg film coated tablets; 2020. https:\/\/www.medicines.org.uk\/emc\/PIL.25958.latest.pdf."},{"key":"S0924933821022434_r8","unstructured":"8. Janssen-Cilag Limited. Summary of product characteristics. TREVICTA 175\u00a0mg, 263\u00a0mg, 350\u00a0mg, 525\u00a0mg prolonged release suspension for injection; 2019. https:\/\/www.medicines.org.uk\/emc\/medicine\/32050."},{"key":"S0924933821022434_r13","unstructured":"13. Janssen Pharmaceutical Companies. Highlights of prescribing information: RISPERDAL\u00ae (risperidone) tablets, RISPERDAL\u00ae (risperidone) oral solution, RISPERDAL\u00ae M-TAB\u00ae (risperidone) orally disintegrating tablets; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020272s082,020588s070,021444s056lbl.pdf."},{"key":"S0924933821022434_r7","unstructured":"7. Janssen-Cilag Ltd. Summary of product characteristics. Xeplion 25\u00a0mg, 50\u00a0mg, 75\u00a0mg, 100\u00a0mg, and 150\u00a0mg prolonged-release suspension for injection; 2018. https:\/\/www.medicines.org.uk\/emc\/medicine\/31329."},{"key":"S0924933821022434_r19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.5.765"},{"key":"S0924933821022434_r2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1161029"},{"key":"S0924933821022434_r18","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S194264"},{"key":"S0924933821022434_r27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071408"},{"key":"S0924933821022434_r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"},{"key":"S0924933821022434_r16","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00990-8"},{"key":"S0924933821022434_r20","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-015-0030-4"},{"key":"S0924933821022434_r29","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320981500"},{"key":"S0924933821022434_r26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00761.x"},{"key":"S0924933821022434_r31","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211009794"},{"key":"S0924933821022434_r21","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.111"},{"key":"S0924933821022434_r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.03.004"},{"key":"S0924933821022434_r15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00809-w"},{"key":"S0924933821022434_r28","doi-asserted-by":"crossref","unstructured":"28. Chung, Y , Yang, Y , Sulaiman, A , Bergman, P , Wea, T . Asian subgroup analysis of the REMISSIO study: a long-term efficacy and safety study of paliperidone palmitate 3-month formulation in patients with stable schizophrenia in a naturalistic clinical setting. Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology. 2021 https:\/\/www.cpn.or.kr\/journal\/view.html?uid=1255&vmd=Full#body01.","DOI":"10.9758\/cpn.2022.20.3.427"},{"key":"S0924933821022434_r11","unstructured":"11. Janssen Pharmaceuticals. Highlights of prescribing information; 2009. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+SUSTENNA-pi.pdf."},{"key":"S0924933821022434_r6","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.683523"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933821022434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:19:26Z","timestamp":1673644766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933821022434\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"alternative-id":["S0924933821022434"],"URL":"https:\/\/doi.org\/10.1192\/j.eurpsy.2021.2243","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e68"}}